Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.51 |
| ▸ | LNPEP | Q9UIQ6 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | VNN1 | O95497 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ASPH | Q12797 | 1/20 | 0.47 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.47 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18995963 | 0.90 | HDAC1 (0.56) | HDAC1ALDH1A1HDAC3HDAC2NCOR2 | |
| SCHEMBL12004538 | 0.90 | GAA (0.54) | HDAC1ALDH1A1CA1CA2HDAC3 | |
| SCHEMBL23286785 | 0.86 | CA1 (0.61) | HDAC1ALDH1A1CA1CA2LNPEP | |
| SCHEMBL7752202 | 0.85 | CA1 (0.52) | HDAC1ALDH1A1CA1CA2HDAC3 | |
| SCHEMBL4315483 | 0.83 | NCF1 (0.53) | HDAC1ALDH1A1CA1CA2MAPT | |
| SCHEMBL16042130 | 0.82 | CA1 (0.50) | HDAC1ALDH1A1CA1CA2HDAC2 | |
| SCHEMBL23286843 | 0.81 | LNPEP (0.46) | HDAC1ALDH1A1CA1CA2LNPEP | |
| SCHEMBL31612035 | 0.80 | MAPT (0.54) | ALDH1A1CA1CA2MAPTKMT2A | |
| SCHEMBL17184370 | 0.80 | MAPT (0.54) | ALDH1A1CA1CA2MAPTKMT2A | |
| SCHEMBL1065928 | 0.80 | HDAC1 (0.71) | HDAC1ALDH1A1CA1CA2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10144742-B2 | Quinoxaline compounds and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| EP-3131881-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2017-02-22 | — | — | EP | disclosed |
| WO-2015161142-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
| WO-2015161142-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | disclosed |
| US-6313122-B1 | AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS | ELI LILLY AND COMPANY | 2001-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10144742-B2 | Quinoxaline compounds and uses thereof | NAMPT, NQO2, NNMT | HDAC1 987/4885ALDH1A1 1374/4885CA1 3815/4885 |
| US-20170174704-A1 | QUINOXALINE COMPOUNDS AND USES THEREOF | NAMPT, NQO2, NNMT | HDAC1 987/4885ALDH1A1 1374/4885CA1 3815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.